DSGN
Design TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Positive clinical updates or faster-than-expected enrollment for one or more GeneTAC programs materially de-risk development and lead analysts to re-rate toward the high-teens price targets, driven by optionality value and limited float.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.9.
What can break
Clinical enrollment or readout delays
Momentum
34
Value
41
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $14.00 · Bull $18.00 · Bear $7.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-03-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $14.40
Why
Momentum34 · Δ7d -51.1
Value41 · Δ7d +0.1
Sentiment81 · Δ7d +9.9
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
34
34% active weight
Current posture
7d trendSoftening
Δ7d
-51.1
Δ21d
-59.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
81
33% active weight
Current posture
7d trendImproving
Δ7d
+9.9
Δ21d
+51.3
Why this grade
Composite grade C. Momentum 33.6 / Value 41.1 / Sentiment 81.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$635.19M
Beta
1.64
Shares Out
56.96M
P/E (TTM) · Derived
-12.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-12.09
Rev YoY
-
EPS YoY
-29.6%
Gross Margin
-
Op Margin
-
Net Debt
-$245.48M
Current Ratio
18.71
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology